Log In
BCIQ
Print this Print this
 

GX-G3

  Manage Alerts
Collapse Summary General Information
Company Genexine Inc.
DescriptionLong acting G-CSF
Molecular Target Granulocyte colony-stimulating factor (G-CSF) (CSF3)
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPhase II
Standard IndicationNeutropenia
Indication DetailsTreat neutropenia
Regulatory Designation
PartnerTasly Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

$80.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/19/2015

Undisclosed

Undisclosed

$80.0M

Get a free BioCentury trial today